FILTER
FILTERED INTERVIEW RESULTS
Ewan Downie
CEO, I-80 GOLD CORP
i-80 Gold Corp. is a gold producer and developer with a wide portfolio of advanced-stage gold projects in Nevada.
Keith Jones
GENERAL MANAGER, SMALL MINE DEVELOPMENT
Small Mine Development explains its service offering and gives insights about new mining methods.
Chris Hodgson
PRESIDENT, ONTARIO MINING ASSOCIATION (OMA)
The Ontario Mining Association explains how safety and ESG are ensured in mines across the province.
Steven Poulton
CEO, ALTUS STRATEGIES
Altus Strategies explains its particular royalty generator model that is primarily focused on Africa.
Franco Pedraz
COUNTRY MANAGER – PERU, WORLEY
Worley speaks to GBR in Peru about how its sustainable solutions for mining are being deployed.
Laxman Shekhawat
EXECUTIVE DIRECTOR AND BUSINESS HEAD, VEDANTA ZINC INTERNATIONAL
Vedanta Zinc International describes progress at its operations in Southern Africa.
Greg Walker
EXECUTIVE MANAGING DIRECTOR, NEVADA GOLD MINES
Nevada Gold Mines explains the rationale behind the creation of the joint venture between Barrick and Newmont and analyzes the potential of its assets.
Jeffrey Quartermaine
CEO, PERSEUS MINING
Perseus Mining finds itself with string cashflows as it develops its third mine.
Nick Tatalias
MANAGING DIRECTOR, METC ENGINEERING
METC Engineering is a medium-sized EPCM company that designs and builds metallurgical plants for mines.
Lisa Davis
CEO, PEARTREE SECURITIES
PearTree Securities explains how investors can benefit from acquiring flow-through shares.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
